Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 9.9.2017 | EN | Official Journal of the European Union | C 299/4 |

---

Prior notification of a concentration

(Case M.8613 — Konica Minolta/Innovation Network Corporation of Japan/Ambry Genetics)

Candidate case for simplified procedure

(Text with EEA relevance)

(2017/C 299/06)

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. | On 1 September 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004[(1)](#ntr1-C_2017299EN.01000401-E0001).  This notification concerns the following undertakings:   |  |  | | --- | --- | | — | Konica Minolta, Inc. (‘KM’, Japan), |  |  |  | | --- | --- | | — | Innovation Network Corporation of Japan (‘INCJ’, Japan), |  |  |  | | --- | --- | | — | Ambry Genetics Corp (‘AG’ USA). |   KM and INCJ indirectly acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of AG.  The concentration is accomplished by way of purchase of shares. |

|  |  |
| --- | --- |
| 2. | The business activities of the undertakings concerned are:  —   for KM: a technology company specialising in imaging products, data analysis optics and nano-fabrication. In this respect, KM develops and manufactures a wide range of hardware and software products that offer solutions to businesses. KM is active in 150 countries, across Europe, USA, Japan, China, Asia and other countries.  —   for INCJ: a public-private partnership of the Japanese Government and 26 private companies. INCJ pursues investment activities by providing financial, technological and management support to next generation businesses. It provides risk capital over the medium to long term to innovative enterprises with a growth potential that brings a value to society.  —   for AG: a healthcare company based in the US. It provides genetic laboratory testing services and is active in related genetic research activities. AG operates in California and focuses its business on the US and Canada with negligible activities in the EU. |

|  |  |
| --- | --- |
| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.  Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004[(2)](#ntr2-C_2017299EN.01000401-E0002) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.  Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:  M.8613 — Konica Minolta/Innovation Network Corporation of Japan/Ambry Genetics  Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:   |  | | --- | | Email: COMP-MERGER-REGISTRY@ec.europa.eu | | Fax +32 22964301 | | Postal address: | | European Commission | | Directorate-General for Competition | | Merger Registry | | 1049 Bruxelles/Brussel | | BELGIQUE/BELGIË | |

---

[Top](#document1)